Cargando…

Targeting Apoptosis Pathways With BCL2 and MDM2 Inhibitors in Adult B-cell Acute Lymphoblastic Leukemia

In adult patients, the treatment outcome of acute lymphoblastic leukemia (ALL) remains suboptimal. Here, we used an ex vivo drug testing platform and comprehensive molecular profiling to discover new drug candidates for B-ALL. We analyzed sensitivity of 18 primary B-ALL adult patient samples to 64 d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hohtari, Helena, Kankainen, Matti, Adnan-Awad, Shady, Yadav, Bhagwan, Potdar, Swapnil, Ianevski, Aleksandr, Dufva, Olli, Heckman, Caroline, Sexl, Veronika, Kytölä, Soili, Mustjoki, Satu, Porkka, Kimmo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8878725/ https://www.ncbi.nlm.nih.gov/pubmed/35233509 http://dx.doi.org/10.1097/HS9.0000000000000701

Ejemplares similares

Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets
por: Adnan-Awad, Shady, et al.
Publicado: (2020)

RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses
por: Adnan Awad, Shady, et al.
Publicado: (2020)

P1228: GENOME-WIDE CRISPR-CAS9 SCREENING IDENTIFIES THERAPEUTIC TARGETS FOR MATURE T-CELL MALIGNANCIES
por: Timonen, Sanna, et al.
Publicado: (2023)

Copy number alterations define outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia
por: Hohtari, Helena, et al.
Publicado: (2022)

Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation
por: Adnan Awad, Shady, et al.
Publicado: (2022)

Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
por: Malani, Disha, et al.
Publicado: (2022)

Immune cell constitution in bone marrow microenvironment predicts outcome in adult ALL
por: Hohtari, Helena, et al.
Publicado: (2019)

Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia
por: Kuusanmäki, Heikki, et al.
Publicado: (2020)

Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia
por: Kuusanmäki, Heikki, et al.
Publicado: (2023)

Breeze: an integrated quality control and data analysis application for high-throughput drug screening
por: Potdar, Swapnil, et al.
Publicado: (2020)

Dasatinib promotes Th1-type responses in granzyme B expressing T-cells
por: Kreutzman, Anna, et al.
Publicado: (2014)

P409: BCL-2/BCL-XL INHIBITION INDUCES APOPTOSIS AND CIRCUMVENTS VENETOCLAX RESISTANCE IN TP53-MUTATED ACUTE MYELOID LEUKEMIA
por: Vänttinen, Ida, et al.
Publicado: (2023)

Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling
por: Kuusanmäki, Heikki, et al.
Publicado: (2017)

Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia
por: White, Brian S., et al.
Publicado: (2021)

Breeze 2.0: an interactive web-tool for visual analysis and comparison of drug response data
por: Potdar, Swapnil, et al.
Publicado: (2023)

Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors
por: Pietarinen, Paavo O., et al.
Publicado: (2017)

Somatic mutations and T-cell clonality in patients with immunodeficiency
por: Savola, Paula, et al.
Publicado: (2019)

Enlarged Memory T-Cell Pool and Enhanced Th1-Type Responses in Chronic Myeloid Leukemia Patients Who Have Successfully Discontinued IFN-α Monotherapy
por: Ilander, Mette, et al.
Publicado: (2014)

Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
por: Dufva, Olli, et al.
Publicado: (2018)

Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia
por: El Missiry, Mohamed, et al.
Publicado: (2017)

Somatic STAT3 mutations in Felty syndrome: an implication for a common pathogenesis with large granular lymphocyte leukemia
por: Savola, Paula, et al.
Publicado: (2018)

Somatic STAT3 mutations in CD8(+) T cells of healthy blood donors carrying human T-cell leukemia virus type 2
por: Kim, Daehong, et al.
Publicado: (2021)

Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types
por: Majumder, Muntasir M., et al.
Publicado: (2020)

The impact of RNA sequence library construction protocols on transcriptomic profiling of leukemia
por: Kumar, Ashwini, et al.
Publicado: (2017)

IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia
por: Huuhtanen, Jani, et al.
Publicado: (2022)

Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity
por: Schiffer, Charles A., et al.
Publicado: (2016)

The SCLtTAxBCR-ABL transgenic mouse model closely reflects the differential effects of dasatinib on normal and malignant hematopoiesis in chronic phase-CML patients
por: Schubert, Claudia, et al.
Publicado: (2017)

Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies
por: Yadav, Bhagwan, et al.
Publicado: (2014)

IDH1 Expression via the R132H Mutation–Specific Antibody in Adrenocortical Neoplasias—Prognostic Impact in Carcinomas
por: Pennanen, Mirkka, et al.
Publicado: (2020)

Clonal dynamics using droplet digital polymerase chain reaction in peripheral blood predicts treatment responses in myelodysplastic syndrome
por: Illman, Johanna, et al.
Publicado: (2022)

STAT3 activation in large granular lymphocyte leukemia is associated with cytokine signaling and DNA hypermethylation
por: Kim, Daehong, et al.
Publicado: (2021)

High-throughput compound screening identifies navitoclax combined with irradiation as a candidate therapy for HPV-negative head and neck squamous cell carcinoma
por: Tuomainen, Katja, et al.
Publicado: (2021)

A novel class of somatic mutations in blood detected preferentially in CD8 + cells
por: Valori, Miko, et al.
Publicado: (2017)

Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia
por: Kuusanmäki, Heikki, et al.
Publicado: (2022)

Chronic Myeloid Leukemia Patients in Prolonged Remission following Interferon-α Monotherapy Have Distinct Cytokine and Oligoclonal Lymphocyte Profile
por: Kreutzman, Anna, et al.
Publicado: (2011)

T and NK cell abundance defines two distinct subgroups of renal cell carcinoma
por: Lee, Moon Hee, et al.
Publicado: (2022)

Comparison of Structural and Short Variants Detected by Linked-Read and Whole-Exome Sequencing in Multiple Myeloma
por: Kumar, Ashwini, et al.
Publicado: (2021)

Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma
por: Van Goethem, Alan, et al.
Publicado: (2017)

Bcl-2: Live and let die
por: Putz, Eva Maria, et al.
Publicado: (2012)

Patient-tailored design for selective co-inhibition of leukemic cell subpopulations
por: Ianevski, Aleksandr, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_genp7ftsbf2b3dnslfpbfpagul